The infliximab group accumulated higher drug and healthcare costs ( @,@ vs @,@ ; adjusted mean difference @,@ ( @ % CI @,@ to @,@ ) ) , while productivity losses did not differ ( @,@ vs @,@ ; @ ( @ % CI -@ to @,@ ) ) , resulting in higher societal cost compared to the conventional group ( @,@ vs @,@ ; @,@ ( @ % CI @,@ to @,@ ) ) .